Notice of Development of Rulemaking
RULE NO.: RULE TITLE:
64B13-18.002
Formulary of Topical Ocular Pharmaceutical Agents
PURPOSE AND EFFECT: The Board proposes to update the
existing language in this rule to add new pharmaceutical agents.
SUBJECT AREA TO BE ADDRESSED: Formulary of Topical
Ocular Pharmaceutical Agents.
SPECIFIC AUTHORITY: 463.005
FS., 463.0055(2)(a) FS.
LAW IMPLEMENTED: 463.0055
FS.
IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY
THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE NOTICED IN THE NEXT
AVAILABLE
THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE
DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT IS: Joe Baker, Jr., Executive
Director, Board of Optometry,
THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT
IS:
64B13-18.002 Formulary of Topical Ocular
Pharmaceutical Agents.
The topical ocular pharmaceutical formulary consists
of pharmaceutical agents which a certified optometrist is qualified to
administer and prescribe in the practice of optometry pursuant to Section
463.0055(2)(a), F.S. The topical ocular pharmaceutical agents in the formulary
include the following legend drugs alone or in combination in concentrations up
to those specified, or any lesser concentration that is commercially available:
(1) through (4) No change.
(5) NON-STEROIDAL AND STEROIDAL ANTI-INFLAMMATORY
AGENTS
(a) through (l) No change.
(m) Bromfenac 0.09%
(n) Nopafenac 0.1%
(o) Brimonidine tartrate 0.1%
(6) through (9) No change.
Specific
Authority 463.005, 463.0055(2)(a) FS. Law Implemented 463.0055 FS. History–New
3-30-87, Amended 4-5-88, 5-7-90, Formerly 21-18.002, Amended 5-10-92, 1-29-93,
Formerly 21Q-18.002, Amended 8-31-93, 7-30-94, Formerly 61F8-18.002, Amended
2-11-96, 4-21-96, 1-12-97, 6-8-97, Formerly 59V-18.002, Amended 6-15-00, 6-7-05,
________.